Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	108.40B
Revenue (ttm)	22.97B
Net Income (ttm)	383.41M
Shares Out	n/a
EPS (ttm)	0.30
PE Ratio	282.71
Forward PE	n/a
Dividend	2.41 (2.20%)
Ex-Dividend Date	Dec 13, 2024

Volume	9,722
Average Volume	20,147
Open	107.95
Previous Close	107.03
Day's Range	107.46 - 109.45
52-Week Range	49.43 - 78.63
Beta	0.20
RSI	76.36
Earnings Date	Feb 3, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 18,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD